Sci Simple

New Science Research Articles Everyday

# Health Sciences # Cardiovascular Medicine

The Role of EPA in Heart Health

Research shows EPA may help reduce heart disease risk through its effects on lipoproteins.

Lauri Äikäs, Petri T. Kovanen, Martina Lorey, Reijo Laaksonen, Minna Holopainen, Hanna Ruhanen, Reijo Käkelä, Matti Jauhiainen, Martin Hermansson, Katariina Öörni

― 5 min read


EPA and Heart Health EPA and Heart Health Insights disease risk. EPA shows promise in lowering heart
Table of Contents

Cardiovascular disease (CVD) is a big problem in the world today. Many people are trying to find ways to prevent it. One of the interesting ideas is using long-chain omega-3 Fatty Acids, like eicosapentaenoic acid (EPA). You might have heard of EPA in fish oil. Researchers found that taking high doses of EPA can help lower the chances of having heart problems and even save lives. It's like giving your heart a helpful friend.

However, we still don't know exactly how EPA helps the heart. It seems to do something with Lipoproteins, which are tiny particles in the blood that carry fats. These lipoproteins can sometimes lead to heart problems, and we want to figure out how EPA affects them.

What are Lipoproteins?

Lipoproteins are like delivery trucks for fats in our blood. They transport things like Cholesterol and triglycerides. Think of them as the messy delivery service that sometimes crashes into the walls of your arteries. Certain types of lipoproteins can get stuck in the artery walls, causing issues. So, if we can understand how these lipoproteins work, we might find ways to keep our hearts healthy.

Study Design

In a recent study, researchers wanted to see how EPA affects people. They brought in 72 healthy volunteers aged between 18 and 65, but thanks to COVID-19, only 38 people could finish the study. It's like trying to complete a group project with half the team missing!

Participants took a daily dose of EPA in capsule form for 28 days, followed by a week without it. Blood samples were taken at various times to measure everything going on inside their bodies.

Effects of EPA on Fatty Acids

After just a week of taking the EPA capsules, the amount of EPA in the volunteers' blood went up four times. That’s like turning a little stream into a rushing river! This high level stayed for a while but then dropped back down after stopping the capsules. Each person's response to the EPA was different, making it feel like a surprise party where some guests bring gifts, and others don't.

The volunteers also experienced changes in their fatty acids. They had more omega-3 fatty acids and fewer omega-6 fatty acids after the supplementation. This change is essential because a better balance of these fatty acids can help with inflammation and heart health.

Changes in Metabolic Markers

Researchers also looked at how EPA affected other markers in the blood. They found that glucose levels went up, while some other compounds went down. It seems like the body was shifting its energy use, like changing from a gas guzzler to a fuel-efficient car!

Some amino acids, which are building blocks of proteins, increased after taking EPA. The researchers noticed this change might be linked to better metabolic processes in the body.

EPA and Cardiovascular Risk

Taking EPA led to a drop in several markers related to heart health. The amount of triglycerides and cholesterol decreased in the blood after just seven days. It's like cleaning up the clutter in a messy room!

The volunteers' risk of heart disease, as measured by the Coronary Event Risk Test, also improved by about 26%. This was good news, but it was essential to keep in mind that the effects reverted after stopping the capsules—like a balloon losing air when you let it go.

Effects on Lipoproteins

The study found that EPA changed how lipoproteins behaved. After supplementation, the levels of certain lipoproteins and the amount of cholesterol they carried decreased. This change means these lipoproteins were less likely to cause trouble in the arteries.

Interestingly, the number of large lipoproteins decreased significantly, which is a positive sign considering larger particles can be more harmful.

Individual Differences

One fascinating takeaway from the study was that every participant reacted differently. Some had a huge increase in EPA levels, while others had barely any change. It's a reminder that our bodies are unique, like snowflakes, and what works for one person may not always work for another.

Impact of EPA on Lipoprotein Lipidomes

After taking the EPA capsules, the balance of lipids in the lipoproteins shifted. For instance, the proportion of EPA-containing lipids increased while some others decreased. This shift means the lipoprotein "package" was changing, which may help reduce the chances of heart problems.

Conclusion

So, what does all this mean? The study suggests that taking EPA can change the way our bodies handle fats and lipoproteins. It reduces the levels of certain harmful fats while promoting healthier ones, ultimately helping to lower heart disease risk.

The researchers are excited about these findings, but they also acknowledge that there's more to learn. Future studies will help us fully understand how EPA interacts with our bodies and how we can use this knowledge to keep our hearts healthy.

Limitations

However, not everything is rosy. The study had a small group of participants, and it only lasted for a short time. It might not represent everyone, especially those with existing heart conditions. Also, they didn't dive deep into how and why these changes happened, leaving room for future explorers to investigate.

Final Thoughts

In summary, while taking EPA seems beneficial, it’s essential to realize that individual responses can vary. Keeping an eye on overall lifestyle choices, including diet and exercise, will always be crucial for heart health. After all, a balanced approach is like a good recipe — it takes various ingredients to make something delicious!

Original Source

Title: Remodelling of plasma lipoproteins by icosapent ethyl -supplementation and its impact on cardiovascular disease risk markers in normolipidemic individuals

Abstract: BACKGROUND AND AIMSIcosapent ethyl (IPE), an ethyl ester of eicosapentaenoic acid (EPA), can reduce cardiovascular disease (CVD). We examined the effect of IPE-supplementation on lipoprotein subclasses, lipidomes and atherogenic properties. METHODSNormolipidemic volunteers received daily 3.9g of IPE for 28 days. Using three independent metabolomic platforms, the fatty acid and lipoprotein profiles in plasma, and lipidomes of isolated VLDL, LDL and HDL, were determined. Aggregation propensity of LDL and the proteoglycan-binding of apoB-containing plasma lipoproteins, and the cholesterol efflux- inducing capacity of HDL were determined. RESULTSIPE-supplementation increased plasma EPA concentrations by 4-fold with consequent reductions in saturated, monounsaturated, and n-6 polyunsaturated fatty acids. This resulted in reduction of multiple clinical risk markers, including triglyceride-, remnant cholesterol-, and apoB-levels, and 10-year CVD risk score. IPE induced uniform alterations across all lipoprotein classes. However, intrinsic interindividual differences in lipoprotein lipidomes outweighed IPE-induced changes. IPE did not alter LDL aggregation propensity or HDL-mediated cholesterol efflux but reduced the affinity of apoB-lipoproteins for proteoglycans. This correlated with decreased apoB-particle concentration and cholesterol content, alongside changes in specific lipid species in LDL, notably phosphatidylcholine 38:3 previously associated with CVD. CONCLUSIONSIPE-supplementation rapidly increases circulating EPA, which integrates equally into all lipoprotein classes. Reduced proteoglycan binding of apoB-lipoproteins likely contributes to the known IPE-induced reduction in CVD risk. Features associated with increased lipoprotein proteoglycan-binding included characteristics of metabolic syndrome, and specific lipid species. The data underscore persistence of distinct interindividual lipoprotein signatures despite extensive IPE-induced remodelling, highlighting the need for personalised approaches in ASCVD-treatment. STRUCTURED GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=178 SRC="FIGDIR/small/24318042v1_ufig1.gif" ALT="Figure 1"> View larger version (65K): [email protected]@e34893org.highwire.dtl.DTLVardef@1b1d047org.highwire.dtl.DTLVardef@e10703_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOGraphical Abstract:C_FLOATNO The figure summarizes the study design and the main findings of this study. CVD, cardiovascular disease; EPA, eicosapentaenoic acid; FA fatty acid; IPE, icosapent ethyl; LDL, low-density lipoprotein; NMR, nuclear magnetic resonance (spectroscopy). Figure created with BioRender.com. C_FIG

Authors: Lauri Äikäs, Petri T. Kovanen, Martina Lorey, Reijo Laaksonen, Minna Holopainen, Hanna Ruhanen, Reijo Käkelä, Matti Jauhiainen, Martin Hermansson, Katariina Öörni

Last Update: 2024-11-29 00:00:00

Language: English

Source URL: https://www.medrxiv.org/content/10.1101/2024.11.27.24318042

Source PDF: https://www.medrxiv.org/content/10.1101/2024.11.27.24318042.full.pdf

Licence: https://creativecommons.org/licenses/by-nc/4.0/

Changes: This summary was created with assistance from AI and may have inaccuracies. For accurate information, please refer to the original source documents linked here.

Thank you to medrxiv for use of its open access interoperability.

Similar Articles